Epizyme Total Liabilities 2012-2022 | EPZM
Epizyme total liabilities from 2012 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Epizyme Annual Total Liabilities
(Millions of US $) |
| 2021 |
$310 |
| 2020 |
$289 |
| 2019 |
$93 |
| 2018 |
$42 |
| 2017 |
$54 |
| 2016 |
$51 |
| 2015 |
$48 |
| 2014 |
$39 |
| 2013 |
$59 |
| 2012 |
$155 |
| 2011 |
$88 |
Epizyme Quarterly Total Liabilities
(Millions of US $) |
| 2022-03-31 |
$301 |
| 2021-12-31 |
$310 |
| 2021-09-30 |
$317 |
| 2021-06-30 |
$285 |
| 2021-03-31 |
$284 |
| 2020-12-31 |
$289 |
| 2020-09-30 |
$137 |
| 2020-06-30 |
$134 |
| 2020-03-31 |
$111 |
| 2019-12-31 |
$93 |
| 2019-09-30 |
$40 |
| 2019-06-30 |
$46 |
| 2019-03-31 |
$44 |
| 2018-12-31 |
$42 |
| 2018-09-30 |
$31 |
| 2018-06-30 |
$34 |
| 2018-03-31 |
$29 |
| 2017-12-31 |
$54 |
| 2017-09-30 |
$52 |
| 2017-06-30 |
$55 |
| 2017-03-31 |
$49 |
| 2016-12-31 |
$51 |
| 2016-09-30 |
$45 |
| 2016-06-30 |
$46 |
| 2016-03-31 |
$44 |
| 2015-12-31 |
$48 |
| 2015-09-30 |
$48 |
| 2015-06-30 |
$36 |
| 2015-03-31 |
$35 |
| 2014-12-31 |
$39 |
| 2014-09-30 |
$48 |
| 2014-06-30 |
$49 |
| 2014-03-31 |
$50 |
| 2013-12-31 |
$59 |
| 2013-09-30 |
$60 |
| 2013-06-30 |
$66 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
$0 |
| 2012-06-30 |
$0 |
| 2011-12-31 |
$88 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.244B |
$0.037B |
|
Epizyme is a development-stage biopharmaceutical company, focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to the market. The company's proprietary product platform is used to create small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). Epizyme's focus is on inhibiting oncogenic HMTs for the treatment of the underlying causes of associated cancers.
|
